BioSpace News Archive

Kodiak Sciences Inc., a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced that it has commenced an underwritten public offering of $400,000,000 of shares of its common stock.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2020 and provided updates on Company developments, including receipt of CE markings for both the recently developed Logix Smart ABC

Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D. and CFO, Jeff McGroarty, MBA, CPA, will participate in A.G.P.'s Virtual Healthcare Symposium on Thursday, November 19, 2020. Dr. Maccecchini and Mr. McGroarty will host virtual one-on-one meetings with investors to disc

Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 2:40 p.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com . A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global medica

Alzamend Neuro®, Inc. (“Alzamend®” or the “Company”) reminds shareholders, investors and all interested parties that mandatory registration is closing Tuesday morning for the conference call and webcast to be held that day November 17th at 5:00pm ET (2:00pm PT) led by Alzamend’s Founder and Chairman, Milton “Todd” Ault, III, and Stephan Jackman, Alzamend’s CEO and Director.

Covis Group S.à r.l. announced the completion of its acquisition of AMAG Pharmaceuticals, Inc. through the successful tender offer for all of the outstanding shares of common stock of AMAG at $13.75 per share in cash and subsequent merger.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has established a subsidiary, Digestix Bioscience Inc., a company dedicated to the development of medical devices and pharmace

Grant awarded to CHOP and Gustave Roussy to support phase 3 clinical trial developed by Children’s Oncology Group and International Society of Paediatric Oncology Europe Neuroblastoma Group, representing first-ever collaboration between North American and European neuroblastoma consortia

Cerevance, a private drug discovery and development company focused on brain diseases, today announced positive results from a Phase 1b clinical trial evaluating the company’s oral compound, CVN058, in a biomarker study evaluating its potential as a treatment for cognitive impairment associated with schizophrenia (CIAS).

Researchers from The Feinstein Institutes for Medical Research and two other institutions have been awarded a $52 million, five-year grant from the National Institute of Mental Health to lead an international study to understand the trajectory toward schizophrenia in high-risk youth.